bioAffinity Technologies, Inc. — Investor Relations & Filings

bioAffinity Technologies, Inc. is a company focused on developing noninvasive diagnostics and targeted therapeutics for cancer. Its first commercialized product, CyPath® Lung, is a non-invasive laboratory developed test for the early detection of lung cancer. The test is designed for individuals at high risk who have suspicious but indeterminate findings on a low-dose computed tomography (LDCT) scan. CyPath® Lung analyzes patient sputum samples using an automated flow cytometry platform and machine learning to identify cell populations indicative of cancer. This approach aims to improve diagnostic accuracy, reduce unnecessary invasive procedures, and lower associated healthcare costs. The company's core technology is based on a proprietary porphyrin platform that preferentially targets cancer cells, with ongoing research to expand its application to other diagnostics and therapeutics.